国际肿瘤学杂志最新文献

{"title":"Fructose metabolism and tumors","authors":"Zhiping Zhang","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.09.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.09.005","url":null,"abstract":"Increasing sugar intake can be considered as a risk factor for some tumors, such as breast cancer, lung cancer, endometrial cancer, ovarian cancer, gallbladder cancer, pancreatic cancer, etc. Fructose can promote tumor formation and progression by several mechanisms, resulting in poor prognosis and increased chemotherapy resistance. Limitation of fructose consumption can reduce the risk of tumor, delay tumor progre-ssion and improve drug resistance, playing an auxiliary role in tumor treatment. \u0000 \u0000 \u0000Key words: \u0000Neoplasms; Fructose; Metabolism","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"11 1","pages":"536-539"},"PeriodicalIF":0.0,"publicationDate":"2019-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82386719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"miR-205及miR-221在结肠癌患者血清中的水平及其临床意义","authors":"陈卿奇 庞莉 程正 麦芳奇 赵高传, Chen Qingqi Pang Li Cheng Zheng Mai Fangqi Zhao Gaochuan","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.09.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.09.003","url":null,"abstract":"Objective \u0000To investigate the serum levels and clinical significances of microRNA-205 (miR-205) and microRNA-221 (miR-221) in patients with colon cancer. \u0000 \u0000 \u0000Methods \u0000A total of 172 patients with colon cancer (colon cancer group), 130 patients with benign diseases of colon (benign lesion group) and 70 healthy persons (control group) admitted to Central Hospital of Western Hainan from January 2016 to December 2018 were selected. The serum levels of miR-205 and miR-221 in each group were detected, and their relationships with clinicopathological characteristics of patients with colon cancer were analyzed. The diagnostic values of the serum levels of miR-205 and miR-221 in colon cancer were analyzed by receiver operating characteristic (ROC) curve. Pearson correlation analysis was used to analyze the correlation between the serum levels of miR-205 and miR-221. \u0000 \u0000 \u0000Results \u0000The serum levels of miR-205 in colon cancer group, benign lesion group and control group were 2.84±0.96, 1.16±0.27 and 1.05±0.23, with a statistically significant diffe-rence (F=10.113, P<0.001). The serum levels of miR-221 in the three groups were 1.95±0.74, 0.37±0.08 and 0.32±0.05, with a statistically significant difference (F=12.416, P<0.001). Further pairwise comparisons found that the serum levels of miR-205 and miR-221 in colon cancer group were significantly higher than those in benign lesion group and control group (all P<0.001). The serum levels of miR-205 and miR-221 in patients with colon cancer were related with TNM stage (t=5.412, P<0.001; t=6.103, P<0.001), degree of tumor differentiation (t=4.573, P=0.028; t=4.805, P=0.013) and with or without lymph node metastasis (t=5.837, P<0.001; t=7.410, P<0.001). ROC curve analysis showed that the optimal cut-off values of the serum levels of miR-205 and miR-221 for the diagnosis of colon cancer were 2.17 and 1.30, respectively. The area under the curve of the two combined diagnostic method for colon cancer was the largest (0.924, 95%CI: 0.865-0.983), with the sensitivity and specificity of 91.3% and 87.4%. The correlation analysis showed that the serum levels of miR-205 and miR-221 were positively correlated in patients with colon cancer (r=0.837, P<0.001). \u0000 \u0000 \u0000Conclusion \u0000The serum levels of miR-205 and miR-221 are significantly increased in patients with colon cancer, and the two combined detection has a high value for the diagnosis of colon cancer. \u0000 \u0000 \u0000Key words: \u0000Colonic neoplasms; miR-205; miR-221","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"39 12","pages":"526-530"},"PeriodicalIF":0.0,"publicationDate":"2019-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72389060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress of immunotherapy for nasopharyngeal carcinoma","authors":"Shun Qiu, Jie Yang, Qianqian Liu, Xiaojiang Li","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.09.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.09.006","url":null,"abstract":"In recent years, immunotherapy has been highly effective in the treatment of various malignant tumors such as nasopharyngeal carcinoma, showing a good development prospect. At present, immunothe-rapy for nasopharyngeal carcinoma mainly includes tumor vaccine treatment, adoptive immune cell therapy and immunological checkpoint inhibitor treatment. It is of great significance to explore the application and mechanism of immunotherapy in the treatment of nasopharyngeal carcinoma. \u0000 \u0000 \u0000Key words: \u0000Nasopharyngeal neoplasms; Immunotherapy","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"130 1","pages":"540-543"},"PeriodicalIF":0.0,"publicationDate":"2019-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77781436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic effect and mechanism of regulating cellular immune function of chemotherapy combined with PD-1 inhibitor in the first-line treatment of Lewis xenografts","authors":"Fang He, Yan-E Gao, H.-Y. Qi, Qin Li, Chong’an Xu","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.08.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.08.002","url":null,"abstract":"Objective \u0000To investigate the efficacy of chemotherapy combined with programmed death-1 (PD-1) inhibitor in the first-line treatment of Lewis xenografts and its possible mechanism of regulating cellular immune function. \u0000 \u0000 \u0000Methods \u0000Lewis xenografts mouse model was established. The mice were randomly divided into control, chemotherapy, immunotherapy and combination group according to the method of random number table (10 in each group), and each group separately received saline, cisplatinum, PD-1 inhibitor and cisplatinum combined with PD-1 inhibitor. The tumor growth and survival of each group were observed. Flow cytometry was used to detect and compare the proportion of CD8+ T cells and CD4+ CD25+ FOXP3+ regulatory T cells (Treg cells). \u0000 \u0000 \u0000Results \u0000On the second day after treatment, the tumor volume of Lewis xenografts in control group, chemotherapy group, immunotherapy group and combination group were (1 662.0±209.0) mm3, (1 189.2±155.6) mm3, (991.1±146.6) mm3 and (761.7±141.8) mm3, with statistically significant difference (F=29.78, P<0.001). The tumor volume in the three treatment groups were significantly smaller than that in control group, combination group was significantly smaller than chemotherapy group and immunotherapy group, and immunotherapy group was significantly smaller than chemotherapy group (all P<0.05). Three mice died during the experiment (two in control group and one in chemotherapy group). The median survival time of mice in the four groups were 10, 12, 14 and 18 days, with statistically significant difference (χ2=26.06, P<0.001). The median survival time of mice in the three treatment groups were significantly longer than that in control group, combination group was significantly longer than chemotherapy group and immunotherapy group, and immunotherapy group was significantly longer than chemotherapy group (all P<0.05). The proportions of CD8+ T cells in the peripheral blood of the four groups were (28.5±1.2)%, (33.9±2.9)%, (34.0±2.5)% and (42.4±1.5)%, with statistically significant difference (F=21.32, P<0.001). The proportions of CD8+ T cells in the peripheral blood of the three treatment groups were significantly higher than that of control group, and combination group was significantly higher than chemotherapy group and immunotherapy group (all P<0.05). The proportions of CD8+ T cells in the tumor microenvironment of the four groups were (23.5±1.3)%, (26.7±1.4)%, (34.2±2.8)% and (41.3±2.0)%, with statistically significant difference (F=61.65, P<0.001). The proportions of CD8+ T cells in the tumor microenvironment of the three treatment groups were significantly higher than that of control group, combination group was significantly higher than chemotherapy group and immunotherapy group, and immunotherapy group was significantly higher than chemotherapy group (all P<0.05). The proportions of CD4+ CD25+ FOXP3+ Treg cells in the spleen of the four groups were (8.6±0.5)%, (7.2±0.3)%, (6.3±0.4)% and (5.4±0.4)%, with sta","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"47 1","pages":"453-459"},"PeriodicalIF":0.0,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81352388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of perfusion CT quantitative analysis for predicting tumor regression grade after chemoradiothe-rapy in patients with rectal cancer","authors":"Zhe Song, Wei Li, N. Jia, Xiang He, Wenyong Zhou","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.08.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.08.007","url":null,"abstract":"Objective \u0000To explore the value of perfusion CT quantitative analysis for predicting tumor regression grade (TRG) after chemoradiotherapy in patients with rectal cancer. \u0000 \u0000 \u0000Methods \u0000From June 2016 to June 2018, 94 rectal cancer patients diagnosed and treated in Cangzhou Central Hospital of Hebei Province were selected and were divided into reaction group (TRG 3-4) and non-reaction group (TRG 0-2) according to the results of surgical specimens. Perfusion CT was performed in both groups before treatment, and chemoradiothe-rapy and surgery were used. Baseline data and perfusion CT results including blood flow, blood volume, mean transit time (MTT), permeability surface (PS) were compared between the two groups, and receiver operating characteristic (ROC) curve was used to evaluate the predictive efficacy of perfusion CT indexes for chemoradiotherapy responsiveness. \u0000 \u0000 \u0000Results \u0000In this study, a total of 23 cases (24.47%) were responsive to chemoradiotherapy, and 71 cases (75.53%) were not responsive to chemoradiotherapy. Blood flow in reaction group [(38.60±7.13) ml·100 g-1·min-1] was significantly lower than that in non-reaction group [(67.39±11.33) ml·100 g-1·min-1, t=3.273, P=0.001]. MTT in reaction group was significantly longer than that in non-reaction group [(11.12±2.19) s vs. (6.88±1.32) s, t=4.500, P<0.001]. There was no significant difference in blood volume [(4.62±0.73) ml/100 g vs. (5.01±1.04) ml/100 g] and PS [(13.72±3.82) ml·100 g-1·min-1vs. (11.40±2.59) ml·100 g-1·min-1] between the two groups (t=0.818, P=0.415; t=0.409, P=0.683). The best cut-off points of blood flow and MTT for predicting chemoradiotherapy responsiveness were 50.89 ml·100 g-1·min-1 and 8.99 s, the area under the curve (AUC) was 0.825 and 0.922, and the AUC of combined prediction of chemoradiotherapy responsiveness was 0.982, which was significantly better than that of single prediction (Z=2.868, P=0.004; Z=2.051, P=0.004). The accuracy (91.49%) and specificity (90.14%) of combined prediction of chemoradiotherapy responsiveness were significantly better than those of single prediction (blood flow: accuracy 75.53%, specificity 73.24%; MTT: accuracy 79.79%, specificity 78.87%), and the differences were statistically significant (χ2=8.800, P=0.012; χ2=6.766, P=0.034). \u0000 \u0000 \u0000Conclusion \u0000Blood flow and MTT in perfusion CT have great predictive value for chemoradiotherapy responsiveness in patients with rectal cancer. \u0000 \u0000 \u0000Key words: \u0000Tomography; Rectal neoplasms; Neoplasm grading; Efficacy evaluation","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"38 1","pages":"480-484"},"PeriodicalIF":0.0,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73476128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical epidemiological analysis of 2 403 cases of lung cancer","authors":"Yujin Wang, Jingyu Huang, Weidong Hu, Sheng Li, Zhengang Tang, Zetian Yang, Xiao-Yan Shen, Congkuan Song, Fei Li","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.08.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.08.003","url":null,"abstract":"Objective \u0000To understand preliminaryly the epidemiological trend of lung cancer in recent years by retrospective analysis of 2 403 cases of lung cancer in Zhongnan Hospital of Wuhan University from 2013 to 2017. \u0000 \u0000 \u0000Methods \u0000The clinical data of patients with primary bronchogenic cancer diagnosed in Zhongnan Hospital of Wuhan University from 2013 to 2017 were collected. The clinical data such as gender, age, history of tobacco and alcohol, operation, pathological type, clinical stage and epidermal growth factor receptor (EGFR) gene mutation were analyzed statistically. \u0000 \u0000 \u0000Results \u0000A total of 2 403 cases of lung cancer were collected, including 1 766 males and 637 females. There was no significant difference in gender ratio between male and female in five years (χ2=8.481, P=0.075). There were 2 398 cases with age information, the male-to-female ratios of lung cancer patients aged less than 40, 40-49, 50-59, 60-69, 70-79, 80 and over were 0.9∶1.0, 1.4∶1.0, 2.4∶1.0, 3.6∶1.0, 3.4∶1.0 and 3.3∶1.0 respectively, and the difference was statistically significant (χ2=59.004, P<0.001). The composition difference of adenocarcinoma was not statistically significant in five years (χ2=2.165, P=0.705). There was no statistically significant difference in the composition ratio of squamous cell carcinoma (χ2=4.788, P=0.310). Adenocarcinoma accounted for 43.15% (762/1 766) and 81.95% (522/637) of the pathological types of male and female patients respectively, and the difference was statistically significant (P<0.001). Squamous cell carcinoma accounted for 39.01% (689/1 766) and 7.28% (47/637) respectively, and the difference was statistically significant (P<0.001). The proportion of squamous cell carcinoma in smoking patients was 42.99% (583/1 356), which was significantly higher than that in non-smoking patients (14.61%, 153/1 047); the proportion of squamous cell carcinoma in drinking patients was 40.56% (277/683), which was higher than that in non-drinking patients (26.69%, 459/1 720), and the differences were statistically significant (both P<0.001). A total of 1 252 patients underwent surgery, accounting for 52.10% (1 252/2 403) of the total cases. The surgical rate of small cell carcinoma was 21.72% (48/221), and that of non-small cell carcinoma was 55.18% (1 204/2 182). In five years, the surgical rates of lung cancer patients were 55.11% (221/401), 51.53% (252/489), 58.23% (244/419), 53.18% (276/519) and 45.04% (259/575) respectively, and there was significant difference in the proportion of surgical and non-surgical patients in each year (χ2=19.553, P=0.001). A total of 483 patients were tested for EGFR mutation, the EGFR mutation rate was 58.8% (251/427) in adenocarcinoma patients and 15.6% (5/32) in squamous cell carcinoma patients. Among lung cancer patients aged less than 40, 40-49, 50-59, 60-69, 70-79, 80 and over, the proportions of adenocarcinoma were 76.74% (33/43), 62.39% (136/218), 57.73% (381/660), 47.95% (455/949), 52.22% (235/450) and 52.5","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"53 1","pages":"460-465"},"PeriodicalIF":0.0,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75975249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of blood cell parameters in the treatment of small cell lung cancer","authors":"Xia-Bo Shen, Wei Wang, Yueyin Pan","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.08.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.08.011","url":null,"abstract":"Small cell lung cancer is a special type of neuroendocrine tumor in the lungs, which has a poor therapeutic effect, and a short time for resistance to relapse, recurrence and distant metastasis. Therefore, searching for readily available predictive parameters is important for clinical treatment strategy. Some indicators of blood cell parameters have been extensively studied in malignant tumors such as non-small cell lung cancer, breast cancer, gastric cancer and colorectal cancer. In-depth understanding of the role of blood cell parameters in small cell lung cancer and its possible mechanisms are of great value in predicting the curative effect and prognosis of small cell lung cancer. \u0000 \u0000Key words: \u0000Small cell lung carcinoma; Treatment outcome; Forecasting; Blood cell parameters","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"25 1 1","pages":"496-499"},"PeriodicalIF":0.0,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89084055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of red blood cell distribution width in tumors","authors":"Jiannan Ye, Chao Sun, Jian-yong Li, Xin Zhou","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.08.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.08.008","url":null,"abstract":"Red blood cell distribution width (RDW) is a conventional digital index for diagnosis of anemia, and recent studies have found its new clinical significance: high RDW is closely related to prognosis and diagnosis of both solid tumors and hematological tumors in addition to acute and chronic kidney disease, chronic obstructive pulmonary disease and cardiovascular disease. RDW, which is cheap and easily acquired, may offer a new direction for clinical diagnosis and prognosis of tumor though the relevant mechanism is unclear. \u0000 \u0000Key words: \u0000Neoplasms; Prognosis; Red blood cell distribution width","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"1033 1","pages":"485-488"},"PeriodicalIF":0.0,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77200685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of immune checkpoint inhibitors in the comprehensive treatment of advanced non-small cell lung cancer","authors":"Xi-Zhuang Bai, Jinmeng Zhang, Yang Sun, Yongheng An","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.08.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.08.012","url":null,"abstract":"In recent years, immunotherapy has become an important part of the treatment for advanced non-small cell lung cancer (NSCLC). Tumor cells can escape from the body′s immune system by mediating various immune escape mechanisms, among which programmed death-1/programmed death ligand-1 (PD-1/PD-L1) mediated immune escape plays an important role. Currently, chemotherapy, radiotherapy and molecular targeted therapy have certain limitations in the treatment of advanced NSCLC. Recent studies have found that the combined application of PD-1/PD-L1 inhibitor and other treatment methods has certain synergistic effect, thus enhances the anti-tumor effect and further prolongs the survival of patients. Immunotherapy brings not only changes in the treatment patterns of NSCLC, but also challenges in the screening of target population and the management of treatment-related adverse reactions. Summarizing the research progress on immune checkpoint inhibitors in the comprehensive treatment of advanced NSCLC can provide reference for the best treatment of NSCLC. \u0000 \u0000Key words: \u0000Lung neoplasms; Immunotherapy; PD-1/PD-L1; Comprehensive therapy","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"74 1","pages":"500-504"},"PeriodicalIF":0.0,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74751821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical application of exosomal miRNA as biomarker in breast cancer","authors":"Lixia Cao, Zhen-dong Shi, Jingjing Liu","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.07.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.07.007","url":null,"abstract":"MicroRNA (miRNA) has a tumor-specific expression profile and plays an important role in the occurrence and progression of tumors. It is protected from RNase in body fluids through the inclusion of exosomes and translocates genetic information horizontally between breast cancer cells. Recent studies on exosome miRNA have found that it is closely related to the occurrence, diagnosis, treatment and prognosis of breast cancer. The in-depth study in this field can provide theoretical basis for the clinical application of exosome miRNA as a biomarker for breast cancer. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; Exosomes; MicroRNAs; Biomarker","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"25 1","pages":"423-426"},"PeriodicalIF":0.0,"publicationDate":"2019-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82785527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}